Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant Recruiting Phase 1 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0115402 (Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02812420Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before SurgeryTreatment